Cargando…

2.5 Mesenchymal Stem Cell Therapy has significant clinical effect in proteoglycan induced arthritis

Detalles Bibliográficos
Autores principales:	Swart, JF, Backer, MJG, Hofhuis, F, de Jager, W, Prakken, BJ, Kuis, W, Martens, ACM, Wulffraat, NM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334194/ http://dx.doi.org/10.1186/1546-0096-6-S1-S5

Ejemplares similares

Recombinant IL1-RA in the early phase of systemic onset JIA: before the onset of arthritis
por: Vastert, SJ, et al.
Publicado: (2011)

Mesenchymal stem cells and JIA
por: Swart, JF, et al.
Publicado: (2011)

4.5 Defective phosphorylation of the interleukin 18 receptor beta-chain causes impaired NK cell function in systemic onset Juvenile Idiopathic Arthritis
por: de Jager, W, et al.
Publicado: (2008)

Akinra restores the defective IL-18 NK cell axis in steroid naïve systemic onset JIA patients
por: de Jager, W, et al.
Publicado: (2011)

PReS-FINAL-2181: Recombinant il-1ra restores the il-18-nk cell axis in steroid naive systemic juvenile idiopathic arthritis
por: De Jager, W, et al.
Publicado: (2013)

Early effects of Anakinra in corticosteroid naïve SOJIA patients
por: Wulffraat, NM, et al.
Publicado: (2008)

Methotrexate does not primarily affect Foxp3+ regulatory T cells in poly-articular juvenile idiopathic arthritis
por: Vastert, SJ, et al.
Publicado: (2008)

PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
por: Swart, JF, et al.
Publicado: (2013)

Autoimmunity or immune deficiency? On the role and function of regulatory T cells in chronic arthritis
por: Prakken, BJ, et al.
Publicado: (2005)

Etanercept in juvenile idiopathic arthritis: Who will benefit?
por: Otten, MH, et al.
Publicado: (2011)

PReS-FINAL-2107: In vitro investigation into mesenchymal stromal cells as a potential therapeutic in juvenile arthritis
por: Wienke, J, et al.
Publicado: (2013)

Mesenchymal stromal cells suppress synovial fluid-derived t cells from juvenile idiopathic arthritis patients in vitro
por: Wienke, J, et al.
Publicado: (2014)

Adverse events of methotrexate treatment in JIA
por: in ‘t Veld, J, et al.
Publicado: (2011)

Functional human regulatory T cells fail to control autoimmune inflammation due to PKB/c-akt hyperactivation in effector cells
por: Wehrens, EJ, et al.
Publicado: (2011)

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
por: Ruperto, N, et al.
Publicado: (2008)

Treatment of methotrexate (MTX) intolerance: behavioural therapy, versus switch to parenteral MTX versus oral MTX
por: Verkaaik, M, et al.
Publicado: (2011)

Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis
por: Van Dijkhuizen, Pieter E H, et al.
Publicado: (2011)

The proteoglycan bikunin has a defined sequence
por: Ly, Mellisa, et al.
Publicado: (2011)

Safety and immunogenicity of human papillomavirus vaccination in juvenile patients with rheumatic diseases
por: Heijstek, MW, et al.
Publicado: (2011)

Immune Recognition of Citrullinated Proteoglycan Aggrecan Epitopes in Mice with Proteoglycan-Induced Arthritis and in Patients with Rheumatoid Arthritis
por: Markovics, Adrienn, et al.
Publicado: (2016)

Has the rheumatoid arthritis (RA) core outcome set influenced the selection of study outcome measures?
por: Kirkham, Jamie, et al.
Publicado: (2013)

Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study
por: Ruperto, N, et al.
Publicado: (2011)

Monocytes and neutrophils in the inflammatory cascade of systemic onset Juvenile Idiopathic Arthritis
por: ter Haar, N, et al.
Publicado: (2015)

Methotrexate restores effector T cell responsiveness in juvenile idiopathic arthritis
por: Bulatović, Maja, et al.
Publicado: (2011)

PReS-FINAL-1016: Micro vesicles as a magnifying glass; uncovering potential biomarkers in juvenile idiopathic arthritis
por: Keustermans, G, et al.
Publicado: (2013)

Immunomodulatory actions of methotrexate on T cells in juvenile idiopathic arthritis
por: Ćalasan, Maja Bulatović, et al.
Publicado: (2012)

Novel self-epitopes derived from aggrecan, fibrillin, and matrix metalloproteinase-3 drive distinct autoreactive T-cell responses in juvenile idiopathic arthritis and in health
por: Kamphuis, Sylvia, et al.
Publicado: (2006)

The position with fingers on clavicles has no influence on vertical trunk inclination and kyphosis but significantly changes surface topography lordosis angle
por: Wojciech, Glinkowski, et al.
Publicado: (2013)

PReS-FINAL-2146: Trends in prescription of biologics and outcomes of juvenile idiopathic arthritis; results of the Dutch national arthritis and biologicals in children register
por: Otten, MH, et al.
Publicado: (2013)

Tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study
por: De Benedetti, F, et al.
Publicado: (2014)

PReS-FINAL-2100: Methotrexate treatment affects effector, but not regulatory T cells in juvenile idiopathic arthritis
por: Vastert, S, et al.
Publicado: (2013)

The clinical and experimental treatment of Juvenile Idiopathic Arthritis
por: Nijhuis, L, et al.
Publicado: (2023)

Attenuation of Collagen-Induced Arthritis in Mice by Salmon Proteoglycan
por: Yoshimura, Sayuri, et al.
Publicado: (2014)

Measles, Mumps, Rubella serology in juvenile idiopathic arthritis
por: Heijstek, MW, et al.
Publicado: (2008)

What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?
por: Swart, Joost F, et al.
Publicado: (2013)

PReS-FINAL-1003: Intrinsic cd4 and cd8 effector t cell resistance to suppression in the synovial fluid of juvenile idiopathic arthritis patients
por: Petrelli, A, et al.
Publicado: (2013)

Treating juvenile idiopathic arthritis to target: what is the optimal target definition to reach all goals?
por: Schoemaker, Casper G., et al.
Publicado: (2020)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

Development of proteoglycan-induced arthritis depends on T cell-supported autoantibody production, but does not involve significant influx of T cells into the joints
por: Angyal, Adrienn, et al.
Publicado: (2010)

Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis
por: Swart, Joost F, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ueh6a6ki5f1bqdkdsgabv5pv5a